FDA clears subcutaneous Sarclisa Escena for multiple myeloma, showing comparable overall response rates to IV delivery.

The U.S. Food ​and Drug ‌Administration said on Friday ​it has ​approved Sanofi's blood ⁠cancer drug, ​Sarclisa, which ​can be given under the ​skin through ​a wearable injector, ‌offering ⁠multiple ...

Awareness of all the ways prompt injection can be effected will help security teams spot a new generation of attacks.

Sanofi (SNY) wins FDA approval for Sarclisa Escena, a subcutaneously-delivered version of its multiple myeloma therapy ...

Collaboration will leverage the RaniPill® platform to explore oral delivery of PegBio's proprietary portfolio of novel obesity and metabolic disease molecules ~ ~ Agreement expands Rani's obesity fran ...

Approval covers all current IV isatuximab indications and introduces the first oncology product labeled for both OBI and manual SC administration. IRAKLIA (NCT05405166) established noninferiority of ...

Subcutaneous isatuximab is now approved with pomalidomide/dexamethasone, carfilzomib/dexamethasone, and bortezomib/lenalidomide/dexamethasone, aligning SC ...

Autism’s new territory: From camel’s milk and stem cell injections to spelling therapy Elizabeth Bonker is a silent woman ...

Conservative commentator Tucker Carlson has announced a dramatic break with the Republican Party, declaring that there is 'no chance' he will support the GOP in the upcoming midterm elections.

Landmark agreement between a leading virtual care company and a pharmaceutical manufacturer establishes an exclusive telehealth co-marketing ...

Sanofi's Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma Approval based on multiple studies, including the pivotal IRAKLIA phase 3 study which demonstrated non-i ...

It’s tough to avoid the current hype about the health benefits of injecting peptides. Although these substances – essentially, synthetic bits of protein in solution – have long made the rounds in the ...